A comprehensive pan-cancer analysis identified CACYBP as being upregulated in 14 cancers—including lung, liver, colon, pancreatic cancers, and cholangiocarcinoma—while it was downregulated in six cancers, such as kidney renal clear cell carcinoma and prostate cancer. This evidence concerns the gene CACYBP and prostate cancer.